Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

优泌林 70/30 - NMPA Drug Approval Details

Approvals/NMPA/Mixed Protamine Human Insulin Injection (30R)

Approved

生物制品

Mixed Protamine Human Insulin Injection (30R)

LILLY FRANCE🇨🇳 National Medical Products Administration

Approval Date: Aug 23, 2021
Approval ID: 8BYt2xFd5pM
Company: LILLY FRANCE
Type: 生物制品

Approval Details

Approval Id: 8BYt2xFd5pM
Approval Number: 国药准字SJ20160044
Generic Name: 30/70混合重组人胰岛素注射液
Generic Name En: Mixed Protamine Human Insulin Injection (30R)
Trade Name: 优泌林 70/30
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 3ml:300单位(笔芯)
Reg Date: 2021-08-23
Expired Date: 2026-08-22
Company Name: LILLY FRANCE
Production Company Name: LILLY FRANCE
Company Detail Path: /organization/lilly-france
Production Company Detail Path: /organization/lilly-france

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Aug 23, 2021

Approval ID

8BYt2xFd5pM

Type

生物制品

Back to NMPA Approvals